The plausible timeline, reconstructed from Lilly's disclosed trial schedule and standard regulatory review windows, looks roughly like this: Q2-Q3 2026: TRIUMPH-1 and TRIUMPH-2 readouts
Our team at Healthon is here to provide the ongoing support you need
These include feeling nauseated, vomiting, diarrhea, upset stomach, headache, dizziness and a complete loss of appetite
Best of all, there are no long-term contracts you have complete flexibility to continue as long as youd like
Subcutaneous bioavailability is nearly complete thanks to albumin binding conferred by the C20 chain
Researchers interested in this direction can see more details on the efficacy of GLP-1R/GCGR agonists in the treatment of obesity in Sanchez-Garridos review (131)